Alacrity is developing digital biomarkers for clinical oncology. Alacrity's digital biomarkers powers a well-designed RPM solution for immune-related drug toxicity management, and helps draw profound data insights from select patient cohorts. Alacrity's multimodal hardware-software solution unlocks the real-world potential of AI through robust, real-time characterization and digitally personalized management of many cytokine mediated toxicities.